Have you looked into how Bio-Rad Laboratories (BIO Quick QuoteBIO - Free Report) performed internationally during the quarter ending September 2025? Considering the widespread global presence of this maker of instruments used in biomedical research, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.

While analyzing BIO's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.

The company's total revenue for the quarter stood at $653 million, increasing 0.5% year over year. Now, let's delve into BIO's international revenue breakdown to gain insights into the significance of its operations beyond home turf.

Exploring BIO's International Revenue Patterns

Asia generated $121 million in revenues for the company in the last quarter, constituting 18.5% of the total. This represented a surprise of -11.85% compared to the $137.27 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia accounted for $126.4 million (19.4%), and in the year-ago quarter, it contributed $126.9 million (19.5%) to the total revenue.

EMEA accounted for 34% of the company's total revenue during the quarter, translating to $222.2 million. Revenues from this region represented a surprise of +12.53%, with Wall Street analysts collectively expecting $197.46 million. When compared to the preceding quarter and the same quarter in the previous year, EMEA contributed $217.2 million (33.3%) and $205.7 million (31.7%) to the total revenue, respectively.

During the quarter, Other (primarily Canada and Latin America) contributed $39.8 million in revenue, making up 6.1% of the total revenue. When compared to the consensus estimate of $39.79 million, this meant a surprise of +0.03%. Looking back, Other (primarily Canada and Latin America) contributed $41.1 million, or 6.3%, in the previous quarter, and $40.9 million, or 6.3%, in the same quarter of the previous year.

Revenue Forecasts for the International Markets

It is projected by analysts on Wall Street that Bio-Rad will post revenues of $693.11 million for the ongoing fiscal quarter, an increase of 3.8% from the year-ago quarter. The expected contributions from Asia, EMEA and Other (primarily Canada and Latin America) to this revenue are 23.3%, 31.9%, and 5.8%, translating into $161.79 million, $221.09 million, and $40.03 million, respectively.

For the full year, the company is expected to generate $2.58 billion in total revenue, up 0.6% from the previous year. Revenues from Asia, EMEA and Other (primarily Canada and Latin America) are expected to constitute 20.5% ($529.56 million), 32.4% ($835.55 million) and 6.2% ($160.73 million) of the total, respectively.

In Conclusion

The dependency of Bio-Rad on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.

In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.

Currently, Bio-Rad holds a Zacks Rank #4 (Sell), signifying its potential to underperform the overall market's performance in the forthcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Look at Bio-Rad Laboratories' Recent Stock Price Performance

The stock has witnessed an increase of 4.6% over the past month versus the Zacks S&P 500 composite's an increase of 2.4%. In the same interval, the Zacks Medical sector, to which Bio-Rad belongs, has registered an increase of 6.8%. Over the past three months, the company's shares saw an increase of 20.9%, while the S&P 500 increased by 8.2%. In comparison, the sector experienced an increase of 13.3% during this timeframe.